Johnson & Johnson Aktie 943981 / US4781601046
153.63
USD
-1.17
USD
-0.76%
18:26:14
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Johnson Johnson Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Johnson & Johnson | 3.00 | 4.70 | USD |
| 2022 | Johnson & Johnson | 2.52 | 4.45 | USD |
| 2021 | Johnson & Johnson | 2.45 | 4.19 | USD |
| 2020 | Johnson & Johnson | 2.53 | 3.98 | USD |
| 2019 | Johnson & Johnson | 2.57 | 3.75 | USD |
| 2018 | Johnson & Johnson | 2.78 | 3.54 | USD |
| 2017 | Johnson & Johnson | 2.38 | 3.32 | USD |
| 2016 | Johnson & Johnson | 2.73 | 3.15 | USD |
| 2015 | Johnson & Johnson | 2.87 | 2.95 | USD |
| 2014 | Johnson & Johnson | 2.63 | 2.76 | USD |
Gewinn je Aktie- Johnson & Johnson
| 13.7 23 | 6.7 22 | 7.8 21 | 5.5 20 | 5.6 19 | 5.6 18 | 0.5 17 |
Umsatz je Aktie- Johnson & Johnson
| 33.3 23 | 35.7 22 | 35.1 21 | 30.9 20 | 30.6 19 | 29.9 18 | 27.9 17 |
KGV- Johnson & Johnson
| 28.3 23 | 26.2 22 | 21.9 21 | 28.6 20 | 25.9 19 | 22.7 18 | 297 17 |
Johnson & Johnson: Die Aktie (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 13.72 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 |
| Gewinn je Aktie unverwässert | 5.59 | 6.83 | 7.93 | 5.59 | 5.72 | 5.70 | 0.48 |
| Gewinn je Aktie verwässert | 5.53 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 |
| Dividende pro Aktie | 4.70 | 4.45 | 4.19 | 3.98 | 3.75 | 3.54 | 3.32 |
| Gesamtdividendenausschüttung in Mio. | 11’770.00 | 11’682.00 | 11’032.00 | 10’481.00 | 9’917.00 | 9’494.00 | 8’943.00 |
Johnson & Johnson: Unternehmenskennzahlen (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 33.26 | 35.67 | 35.06 | 30.92 | 30.59 | 29.88 | 27.86 |
| KGV (Jahresendkurs, EPS unverwässert) | 28.32 | 26.23 | 21.91 | 28.57 | 25.88 | 22.69 | 297.28 |
| KGV (Jahresendkurs, EPS verwässert) | 28.32 | 26.23 | 21.91 | 28.57 | 25.88 | 22.69 | 297.28 |
| KGV (Jahresendkurs) | 28.32 | 26.23 | 21.91 | 28.57 | 25.88 | 22.69 | 297.28 |
| Dividendenrendite Jahresende in % | 3.00 | 2.52 | 2.45 | 2.53 | 2.57 | 2.78 | 2.38 |
| Eigenkapitalquote in % | 41.04 | 40.99 | 40.67 | 36.18 | 37.70 | 39.07 | 38.24 |
| Fremdkapitalquote in % | 58.96 | 59.01 | 59.33 | 63.82 | 62.30 | 60.93 | 61.76 |
Johnson & Johnson: GuV (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 85’152.00 | 95’015.00 | 93’758.00 | 82’572.00 | 82’113.00 | 81’534.00 | 76’481.00 |
| Umsatzveränderung in % | -10.38 | 1.34 | 13.55 | 0.56 | 0.71 | 6.61 | 6.32 |
| Bruttoergebnis vom Umsatz | 58’722.00 | 64’297.00 | 63’884.00 | 54’574.00 | 54’978.00 | 54’348.00 | 51’374.00 |
| Bruttoergebnisveränderung in % | -8.67 | 0.65 | 17.06 | -0.73 | 1.16 | 5.79 | 2.14 |
| Operatives Ergebnis | 22’162.00 | 24’780.00 | 24’481.00 | 20’468.00 | 21’550.00 | 21’253.00 | 19’565.00 |
| Veränderung Operatives Ergebnis in % | -10.56 | 1.22 | 19.61 | -5.02 | 1.40 | 8.63 | -8.36 |
| Ergebnis vor Steuern | 15’062.00 | 21’725.00 | 22’776.00 | 16’497.00 | 17’328.00 | 17’999.00 | 17’673.00 |
| Veränderung Ergebnis vor Steuern in % | -30.67 | -4.61 | 38.06 | -4.80 | -3.73 | 1.84 | -10.76 |
| Ergebnis nach Steuer | 13’326.00 | 17’941.00 | 20’878.00 | 14’714.00 | 15’119.00 | 15’297.00 | 1’300.00 |
| Veränderung Ergebnis nach Steuer in % | -25.72 | -14.07 | 41.89 | -2.68 | -1.16 | 1’076.69 | -92.14 |
Johnson & Johnson: Bilanz (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 98’784 | 110’574 | 107’995 | 111’616 | 98’257 | 93’202 | 97’143 |
| Langzeit Gesamtverbindlichk. pro Aktie | 21.81 | 20.96 | 23.88 | 26.26 | 23.66 | 23.28 | 24.83 |
| Eigenkapital | 68’774 | 76’804 | 74’023 | 63’278 | 59’471 | 59’752 | 60’160 |
| Veränderung Eigenkapital in % | -10.46 | 3.76 | 16.98 | 6.40 | -0.47 | -0.68 | -14.57 |
| Bilanzsumme | 167’558 | 187’378 | 182’018 | 174’894 | 157’728 | 152’954 | 157’303 |
| Veränderung Bilanzsumme in % | -10.58 | 2.94 | 4.07 | 10.88 | 3.12 | -2.76 | 11.40 |
Johnson & Johnson: Sonstige Angaben (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 5.59 | 6.83 | 7.93 | 5.59 | 5.72 | 5.70 | 0.48 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -18.17 | -13.84 | 41.93 | -2.22 | 0.28 | 1’087.50 | -92.05 |
| Gewinn je Aktie (verwässert) | 5.53 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 |
| Veränderung Gewinn je Aktie (verwässert) in % | -17.83 | -13.74 | 41.72 | -2.18 | 0.40 | 1’093.62 | -92.07 |
| Anzahl Mitarbeiter | 131’900 | 152’700 | 141’700 | 134’500 | 132’200 | 135’100 | 134’000 |
| Veränderung Anzahl Mitarbeiter in % | -13.62 | 7.76 | 5.35 | 1.74 | -2.15 | 0.82 | 6.01 |
Johnson & Johnson Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Johnson & Johnson | Quartalszahlen | 22.01.2025 |
| Johnson & Johnson | Quartalszahlen | 15.04.2025 |
| Johnson & Johnson | Quartalszahlen | 22.07.2025 |
| Johnson & Johnson | Quartalszahlen | 21.10.2025 |
Johnson & Johnson vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 15.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 17.07.2024 |
| Hauptversammlung | Annual General Meeting | 25.04.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 16.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 23.01.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 17.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 20.07.2023 |
| Hauptversammlung | Annual General Meeting | 27.04.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 18.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 24.01.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 18.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 19.07.2022 |
| Hauptversammlung | Annual General Meeting | 28.04.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 19.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 25.01.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.88 |
| The Vanguard Group, Inc. | 9.53 |
| Vanguard Group, Inc. (Subfiler) | 9.15 |
| State Street Corp. | 5.58 |
| SSgA Funds Management, Inc. | 5.52 |
| Vanguard Total Stock Market ETF | 3.16 |
| BlackRock Fund Advisors | 3.11 |
| Vanguard 500 Index Fund | 2.65 |
| Geode Capital Management LLC | 2.33 |
| BlackRock Institutional Trust Co. NA | 2.21 |
| State Farm Investment Management Corp. | 1.32 |
| Fidelity 500 Index Fund | 1.23 |
| SPDR S&P 500 ETF Trust | 1.21 |
| Norges Bank (13F) | 1.21 |
| iShares Core S&P 500 ETF | 1.11 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 134’000 | 135’100 | 132’200 | 134’500 | 141’700 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.57 | 0.60 | 0.62 | 0.61 | 0.66 |
Bilanz (in Mio. USD) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 43’088 | 46’033 | 45’274 | 51’237 | 60’979 |
| Summe Anlagevermögen | 114’215 | 106’921 | 112’454 | 123’657 | 121’039 |
| Summe Aktiva | 157’303 | 152’954 | 157’728 | 174’894 | 182’018 |
Bilanz (in Mio. USD) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 97’143 | 93’202 | 98’257 | 111’616 | 107’995 |
| Summe Eigenkapital | 60’160 | 59’752 | 59’471 | 63’278 | 74’023 |
| Summe Passiva | 157’303 | 152’954 | 157’728 | 174’894 | 182’018 |
Adresse
| One Johnson & Johnson Plaza, 08933 New Brunswick | |
| Telefon | +1 (732) 524-0400 |
| URL | http://www.jnj.com |
Management
|
Anne M. Mulcahy
Independent Director |
|
Caroline Tillett
Global Head-Consumer Health |
|
Darius Adamczyk
Independent Director |
|
Elizabeth Forminard
Executive Vice President & General Counsel |
|
Eugene A. Woods
Independent Director |
|
George Davy
Global HR Director |
|
Hubert Joly
Independent Director |
|
James D. Swanson
Chief Information Officer & Executive VP |
|
Jennifer A. Doudna
Independent Director |
|
Jennifer L. Taubert
EVP & Worldwide Chairman-Innovative Medicine |
|
Jessica Moore
Vice President-Investor Relations |
|
Joaquin Duato
Chairman & Chief Executive Officer |
|
John C. Reed
Executive Vice President-Innovative Medicine |
|
Jonathan Sheh
Director-Workplace Experience |
|
Joseph J. Wolk
Chief Financial Officer & Executive Vice President |
|
Juliana Clawson
Head-Global Quality & Compliance |
|
Kathryn E. Wengel
Chief Technical Operations & Risk Officer |
|
Kristen Blair Mulholland
Chief Human Resources Officer & Executive VP |
|
Lisa Paley
Vice President-US Sales |
|
Marc Larkins
Secretary & Vice President-Governance |
|
Marillyn A. Hewson
Lead Independent Director |
|
Mark Alan Weinberger
Independent Director |
|
Mark B. McClellan
Independent Director |
|
Mary C. Beckerle
Independent Director |
|
Meredith Stevens
Vice President |
|
Michael Bzdak
Global Dir-Employee Engagement-Global Cmnty Impact |
|
Nadja Y. West
Independent Director |
|
Neil Ackerman
Head-Innovation, Global Supply & Transformation |
|
Paul Ruh
Chief Financial Officer-Consumer Health |
|
Paula A. Johnson
Independent Director |
|
Robert J. Decker
Chief Accounting Officer & Controller |
|
Ronald A. Kapusta
Chief Accounting Officer & Controller |
|
Thomas J. Spellman
Secretary |
|
Timothy Schmid
Executive Vice President & Chairman-Worldwide |
|
William E. Cohn
Vice President-Medical Devices |
|
William N. Hait
Chief External Innovation & Executive VP-Medical |